ArticleJTO clinical and research reports2025

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations.

Jonathan W Riess et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.